Research theme for competitive and other funds (6)：
2022 - 2026 癌領域の医薬品、診断薬、再生医療の開発早期に必要な臨床データに関する研究
2019 - 2022 遺伝子パネル検査によるコンパニオン診断システムの標準化に向けた検討
2018 - 2022 抗癌剤の早期アクセスに資する条件付き承認制度の運用方法の検討
2015 - 2018 Clinical data for conditional approval of regenerative medical products for cancer
2011 - 2011 急性骨髄性白血病予後不良因子BAALCの機能解析
2009 - 2010 急性骨髄性白血病予後不良因子の機能解析
Show all
Papers (40)：
Kensuke Matsuda, Sumimasa Nagai, Koichi Sugimoto. Drug approval delays in hematologic malignancies between Europe and the US and between Japan and the US: a clinical perspective. Japanese journal of clinical oncology. 2023. 53. 12. 1125-1129
Sumimasa Nagai, Hiroshi Nishihara, Takayoshi Suzuki, Kazuto Nishio, Hiroya Taniguchi, Katsuya Tsuchihara, Kohei Nakamura, Reika Takamatsu, Toshihide Ueno, Hiroyuki Aburatani, et al. Recommendations related to the analytical equivalence assessment of gene panel testing. Cancer science. 2022. 113. 10. 3282-3290
Hidenori Kage, Shinji Kohsaka, Kenji Tatsuno, Toshihide Ueno, Masachika Ikegami, Koichi Zokumasu, Aya Shinozaki-Ushiku, Sumimasa Nagai, Hiroyuki Aburatani, Hiroyuki Mano, et al. Tumor mutational burden measurement using comprehensive genomic profiling assay. Japanese journal of clinical oncology. 2022. 52. 8. 917-921
Gita Thanarajasingam, Lori M Minasian, Vishal Bhatnagar, Franco Cavalli, R Angelo De Claro, Amylou C Dueck, Tarec C El-Galaly, Neil Everest, Jan Geissler, Christian Gisselbrecht, et al. Reaching beyond maximum grade: progress and future directions for modernising the assessment and reporting of adverse events in haematological malignancies. The Lancet. Haematology. 2022. 9. 5. e374-e384
Sumimasa Nagai, Bartlett Witherspoon, Chadi Nabhan, Charles L Bennett. Biosimilar Epoetin in the United States: A View from the Southern Network on Adverse Reactions. Cancer treatment and research. 2022. 184. 41-51
